Clinical trials: Peyronie Disease
Peyronie Disease
Safety and Efficacy of Intralesional HiLow Hyaluronic Acid in the Treatment of Peyronie's Disease (PD)
Prospective, open-label, single-arm, multicentric, pilot clinical study to confirm the safety of HiLow hyaluronic acid sodium salt for intralesional penile injection in patients affected by PD.
- Trial name
- NCT05871177
- Testing
- Pre-filled syringe of HiLow Hyaluronic Acid Sodium Salt
- Where
- 3 sites in Italy
- Volunteers
- 40 people
- Sponsor
- IBSA Farmaceutici Italia Srl
Peyronie's Disease
Real-World Data Study to Understand Effectiveness of Treatments in Peyronie's Disease
This is an observational study, meaning participants will not receive any investigational treatment as part of this study. Researchers will collect real-world data (RWD) to gain a more in-depth knowledge of the treatment of…
- Trial name
- CURVE-PD (NCT05873595)
- Where
- 7 sites in United States
- Volunteers
- 29 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Peyronie's Disease
A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease
This study is a Phase 3, open-label study of the safety and efficacy of AA4500 0.58 mg in subjects with Peyronie's disease. Subjects will be screened for study eligibility within 21 days before the initial injection of study drug…
- Trial name
- NCT01685437
- Testing
- AA4500
- Volunteers
- 189 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Peyronie's Disease
Additional Xiaflex® Treatment in Patients With Peyronie's Disease Recurrence, Worsening, or Incomplete Response
Subjects who have had an incomplete response to previous Xiaflex® will receive up to 4 additional cycles of treatment.
- Trial name
- NCT03767452
- Testing
- Xiaflex® 0.58 mg
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Manhattan Medical Research Practice, PLLC
Peyronie's Disease
An Open-label Study to Assess the Safety and Effectiveness of AA4500 in Combination With the ErecAid® Esteem® Manual Vacuum Therapy System in Treating Men With Peyronie's Disease
Enrollment will include approximately 30 AA4500 naïve subjects. Subjects will be divided by degree of penile curvature and then randomized in a 1:1 ratio to one of the following treatment groups: AA4500 with investigator modeling…
- Trial name
- NCT02267460
- Testing
- AA4500, ErecAid® Esteem® Manual Vacuum Therapy System, Investigator Modeling
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Peyronie's Disease
Peyronie's Disease Treatment Protocol
Treatment of Peyronie's disease remains difficult. The purpose of this study is to test the safety and efficacy of a new compound to treat this disease.
- Trial name
- NCT02072018
- Testing
- H-100
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Hybrid Medical
Peyronie's Disease
Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease
This study is a Phase 2, open-label study to assess the pharmacokinetics (PK) and safety of AA4500 0.58 mg in men with Peyronie's disease.
- Trial name
- NCT01430169
- Testing
- AA4500
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Peyronie's Disease
Study of AA4500 in the Treatment of Peyronie's Disease
This study is a Phase 3, double-blind, randomized, placebo-controlled study of the safety and efficacy of AA4500 0.58 mg in subjects with Peyronie's disease. Approximately 400 (267 AA4500 and 133 placebo) men will be randomized.
- Trial name
- NCT01221597
- Testing
- AA4500
- Where
- 34 sites in United States, Australia
- Volunteers
- 418 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Peyronie's Disease
A Study of AA4500 in Men With Peyronie's Disease
This study is a Phase 3, open-label study of the safety and efficacy of AA4500 0.58 mg in subjects with Peyronie's disease. Subjects will be screened for study eligibility within 21 days before the initial injection of study drug…
- Trial name
- NCT01243411
- Testing
- AA4500
- Where
- 39 sites in United States, Denmark and 7 more
- Volunteers
- 348 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Peyronie's Disease
The Safety and Effectiveness of AA4500 in Subjects With Peyronie's Disease
This study evaluated the safety and effectiveness of AA4500 in improving the impact of Peyronie's disease on quality of life and improving penile curvature in men with Peyronie's disease
- Trial name
- NCT00755222
- Testing
- AA4500
- Where
- 12 sites in United States
- Volunteers
- 147 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Peyronie's Disease
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease
This a Phase 4 non-treatment, long-term follow-up study of subjects who received AA4500 in a 12-month double blind placebo-controlled study (AUX CC 803 or AUX-CC-804) or in a 9-month open label study (AUX-CC-802 or AUX-CC-806)…
- Trial name
- NCT02298829
- Testing
- Subjects Previously Treated with AA4500
- Where
- 30 sites in United States
- Volunteers
- 184 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Peyronie's Disease
Study of AA4500 in the Treatment of Peyronie's Disease
This study is a Phase 3, double-blind, randomized, placebo-controlled study of the safety and efficacy of AA4500 0.58 mg in subjects with Peyronie's disease. Approximately 300 (200 AA4500 and 100 placebo) men will be randomized.
- Trial name
- NCT01221623
- Testing
- AA4500
- Where
- 34 sites in United States, Australia
- Volunteers
- 418 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company